Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas C Turner

Showing results (21-30 of 138) with videos related to

Pageof 14
Sort By:
Cancer Discovery|October 2, 2021
Heterogeneous <i>HER2</i> Amplification-a New Clinical Category of HER2-Positive Breast Cancer?Alicia F C Okines, Nicholas C Turner
Breast Cancer Research : BCR|November 14, 2012
Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?Nicholas C Turner, Andrew N J Tutt
Nature Reviews. Clinical Oncology|December 11, 2023
The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatmentLaura Morrison, Sibylle Loibl, Nicholas C Turner
The New England Journal of Medicine|January 15, 2025
Inavolisib Therapy in Advanced Breast Cancer. ReplyNicholas C Turner, Eirini Thanopoulou, Komal L Jhaveri
Nature Reviews. Clinical Oncology|April 1, 2016
Treating cancer with selective CDK4/6 inhibitorsBen O'Leary, Richard S Finn, Nicholas C Turner
The New England Journal of Medicine|October 22, 2015
Palbociclib in Hormone-Receptor-Positive Advanced Breast CancerNicholas C Turner, Cynthia Huang Bartlett, Massimo Cristofanilli
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2019
Molecular Residual Disease and Adjuvant Trial Design in Solid TumorsMaria Coakley, Isaac Garcia-Murillas, Nicholas C Turner
Plos One|January 4, 2014
Determination of HER2 amplification status on tumour DNA by digital PCRIsaac Garcia-Murillas, Maryou Lambros, Nicholas C Turner
Cancer Discovery|March 8, 2017
Gatekeeper Mutations and Intratumoral Heterogeneity in <i>FGFR2</i>-Translocated CholangiocarcinomaElizabeth C Smyth, Irina S Babina, Nicholas C Turner
Lancet (London, England)|December 13, 2016
Advances in the treatment of advanced oestrogen-receptor-positive breast cancerNicholas C Turner, Patrick Neven, Sibylle Loibl, et al.
Pageof 14

Showing results (21-30 of 138) with videos related to

Sort By:
Pageof 14
Cancer Discovery|October 2, 2021
Heterogeneous <i>HER2</i> Amplification-a New Clinical Category of HER2-Positive Breast Cancer?Alicia F C Okines, Nicholas C Turner
Breast Cancer Research : BCR|November 14, 2012
Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?Nicholas C Turner, Andrew N J Tutt
Nature Reviews. Clinical Oncology|December 11, 2023
The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatmentLaura Morrison, Sibylle Loibl, Nicholas C Turner
The New England Journal of Medicine|January 15, 2025
Inavolisib Therapy in Advanced Breast Cancer. ReplyNicholas C Turner, Eirini Thanopoulou, Komal L Jhaveri
Nature Reviews. Clinical Oncology|April 1, 2016
Treating cancer with selective CDK4/6 inhibitorsBen O'Leary, Richard S Finn, Nicholas C Turner
The New England Journal of Medicine|October 22, 2015
Palbociclib in Hormone-Receptor-Positive Advanced Breast CancerNicholas C Turner, Cynthia Huang Bartlett, Massimo Cristofanilli
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2019
Molecular Residual Disease and Adjuvant Trial Design in Solid TumorsMaria Coakley, Isaac Garcia-Murillas, Nicholas C Turner
Plos One|January 4, 2014
Determination of HER2 amplification status on tumour DNA by digital PCRIsaac Garcia-Murillas, Maryou Lambros, Nicholas C Turner
Cancer Discovery|March 8, 2017
Gatekeeper Mutations and Intratumoral Heterogeneity in <i>FGFR2</i>-Translocated CholangiocarcinomaElizabeth C Smyth, Irina S Babina, Nicholas C Turner
Lancet (London, England)|December 13, 2016
Advances in the treatment of advanced oestrogen-receptor-positive breast cancerNicholas C Turner, Patrick Neven, Sibylle Loibl, et al.
Pageof 14